InvestorsHub Logo
Followers 314
Posts 10713
Boards Moderated 16
Alias Born 02/24/2010

Re: Giovanni post# 1900

Wednesday, 12/01/2021 5:19:32 PM

Wednesday, December 01, 2021 5:19:32 PM

Post# of 2139
$HEPA
Just so everyone knows that AKRO is starting a 2b Trial for NASH with Fast Track Designation, but has a greatly inferior drug, yet is trading at $20+ with PT in $60+.

So to be comparable, although CRV431 is a much more superior drug WITH MULTIPLE OTHER INDICATIONS, HEPA’s stock should be trading at $10+ with PT of $30+ just to be equally valued…when CRV431 is vastly more valuable!!!

Posted on ST
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News